EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Outcomes of [177Lu]Lu-PSMA-617 in Patients with mCRPC Treated with or without Concurrent ARPI: A Real-World Single-Center Analysis

M Rust, D Ventura, C Backhaus, O Platte, B Matheja, S Pfeiffer, M Schäfers, L Stegger, W Roll, K Rahbar

Nuklearmedizin - NuclearMedicine · 01.04.2026 · 65 (02) · 114

DOI: 10.1055/s-0046-1818209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.04.2026. Verfasst von M Rust und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ziel/Aim: [ 177 Lu]Lu-PSMA-617 has been approved following VISION trial, demonstrating a significant outcome benefit in patients with metastatic castration-resistant prostate cancer (mCRPC) when added to the best standard of care. This study aimed to evaluate the efficacy and clinical outcomes of recently approved [ 177 Lu]Lu-PSMA-617 radioligand therapy administered with or without concurrent Androgen Receptor Pathway inhibitors (ARPI) in a real-world setting. Methodik/Methods: We conducted a retrospective analysis of clinical data obtained from electronic health records of patients treated with [ 177 Lu]Lu-PSMA-617 in routine clinical settings following regulatory approval between June 2023 and August 2024. Baseline demographics and clinical characteristics were compared between treatment groups using the Mann–Whitney U test and chi-square test. Efficacy endpoints included PSA50 response and duration, median number of previous therapy lines, PSA progression-free survival (PFS), PET-based PFS, and overall survival (OS). Survival analyses were performed using the Kaplan–Meier method, and univariate as well as multivariate regression models were applied to identify factors associated with survival outcomes. Ergebnisse/Results: Among 100 patients, 42 received [ 177 Lu]Lu-PSMA-617 with concurrent ARPI. Median duration of follow-up for those treated with ARPI versus [ 177 Lu]Lu-PSMA-617 alone was 12.3 vs. 13.3 months (IQR 7.6-17.4 vs. 5.0-18.9; p =0.724). PSA50 response rate was 52.4% vs. 50% ( p =0.814). Median response duration was 4.0 vs. 5.0 months ( p =0.357). Median number of previous therapy lines was 4 vs. 5 ( p =0.198). Median PSA-PFS was identical with 5.0 months ( p =0.635). Median PET-based PFS was 11.0 vs. 10.0 months ( p =0.387). Median overall survival was 12.7 vs 13.5 months ( p =0.911). Schlussfolgerungen/Conclusion: In this real-world analysis, concurrent ARPI treatment did not provide statistically significant predictive or prognostic value. These findings highlight the need to consider the cost-effectiveness of combined treatment approaches in mCRPC management. Publication History Article published online: 02 April 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Rust, M., Ventura, D., Backhaus, C., Platte, O., Matheja, B., Pfeiffer, S., Schäfers, M., Stegger, L., Roll, W., & Rahbar, K. (2026). Efficacy and Outcomes of [177Lu]Lu-PSMA-617 in Patients with mCRPC Treated with or without Concurrent ARPI: A Real-World Single-Center Analysis. Nuklearmedizin - NuclearMedicine, 65(02), 114. https://doi.org/10.1055/s-0046-1818209

Vancouver

Rust M, Ventura D, Backhaus C, Platte O, Matheja B, Pfeiffer S, et al. Efficacy and Outcomes of [177Lu]Lu-PSMA-617 in Patients with mCRPC Treated with or without Concurrent ARPI: A Real-World Single-Center Analysis. Nuklearmedizin - NuclearMedicine. 2026;65(02):114. doi:10.1055/s-0046-1818209

BibTeX
@article{Rust2026,
  author = {Rust, M and Ventura, D and Backhaus, C and Platte, O and Matheja, B and Pfeiffer, S and Schäfers, M and Stegger, L and Roll, W and Rahbar, K},
  title = {Efficacy and Outcomes of [177Lu]Lu-PSMA-617 in Patients with mCRPC Treated with or without Concurrent ARPI: A Real-World Single-Center Analysis},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2026},
  volume = {65},
  number = {02},
  pages = {114},
  doi = {10.1055/s-0046-1818209}
}
Kostenlos starten →